Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Subcutaneous Insulin Glargine in DKA
NCT02930044Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2016
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of insulin glargine in diabetic ketoacidosis (DKA) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Duration of intravenous insulin infusion up to 10 months. Started Oct 2016; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetic ketoacidosis (DKA)
Beyond the preview
Go deeper on NCT02930044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930044.